Hetero Drugs
- All
- News
- Videos
-
Drug Firm Hetero Gets Approval To Produce, Sell Sputnik Light Vaccine
Drug firm Hetero on Monday said its biologics arm has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell Sputnik Light for restricted emergency use in India.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Hetero Launches Colorectal Cancer Drug In India
Drug firm Hetero on Monday launched a biosimilar of 'Bevacizumab', used in treating metastatic colorectal cancer (mCRC), under the brand name 'CizumabTM'.
-
Germany's Stada Agrees Oncology Deal With Hetero Drugs
German generics drug maker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.
-
Dr Reddy's Labs Gains on Plans to Launch Hepatitis C Drug
Hetero had signed a non-exclusive agreement with Gilead Sciences to manufacture and sell its Hepatitis medicines.
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Aurobindo Pharma to move Tribunal against attachment of property
Aurobindo Pharma is preparing to challenge before the Appellate Tribunal an order that allowed Enforcement Directorate (ED) to take possession of attached property and fixed deposits worth Rs 12.90 crore in connection with money laundering probe against YSR Congress chief Jagan Mohan Reddy and his associates.
-
Drug Firm Hetero Gets Approval To Produce, Sell Sputnik Light Vaccine
Drug firm Hetero on Monday said its biologics arm has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell Sputnik Light for restricted emergency use in India.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Hetero Launches Colorectal Cancer Drug In India
Drug firm Hetero on Monday launched a biosimilar of 'Bevacizumab', used in treating metastatic colorectal cancer (mCRC), under the brand name 'CizumabTM'.
-
Germany's Stada Agrees Oncology Deal With Hetero Drugs
German generics drug maker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.
-
Dr Reddy's Labs Gains on Plans to Launch Hepatitis C Drug
Hetero had signed a non-exclusive agreement with Gilead Sciences to manufacture and sell its Hepatitis medicines.
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Aurobindo Pharma to move Tribunal against attachment of property
Aurobindo Pharma is preparing to challenge before the Appellate Tribunal an order that allowed Enforcement Directorate (ED) to take possession of attached property and fixed deposits worth Rs 12.90 crore in connection with money laundering probe against YSR Congress chief Jagan Mohan Reddy and his associates.
